Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics Inc. (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in endocrinology, women’s health, immunology, and oncology. The ABCL news feed on Stock Titan aggregates company announcements, clinical updates, financial disclosures, and other material events drawn from AbCellera’s press releases and regulatory filings.
Investors and followers of ABCL can use this page to review news on AbCellera’s internal pipeline, including its lead programs ABCL635 and ABCL575. Recent announcements describe ABCL635 as a potential first-in-class non-hormonal antibody treatment for moderate-to-severe vasomotor symptoms associated with menopause, now in a Phase 1/2 clinical trial, and ABCL575 as an Fc-silenced, half-life extended investigational antibody therapy in a Phase 1 study for moderate-to-severe atopic dermatitis with potential applications in other inflammatory and autoimmune conditions.
The ABCL news stream also captures business and corporate developments, such as quarterly business results, updates on partner-initiated programs and molecules in the clinic, and changes in leadership and board composition. In addition, it includes disclosures on legal and intellectual property matters, including AbCellera’s settlement and patent license agreement with Bruker Corporation that resolved patent litigation globally and provides for upfront and royalty payments.
By reviewing this curated news page, readers can follow how AbCellera advances its antibody discovery and development engine, expands its clinical-stage pipeline, and manages its partnered programs and intellectual property. Bookmark this ABCL news section to quickly access company-issued updates, earnings announcements, clinical trial milestones, and other material information relevant to AbCellera’s operations and strategy.
AbCellera (Nasdaq: ABCL) will report first quarter 2026 financial results on May 11, 2026 and hold an earnings conference call at 2:00 p.m. PT / 5:00 p.m. ET the same day.
A live audio webcast and replay will be available through a link on AbCellera's investor relations website.
AbCellera (Nasdaq: ABCL) reported full-year 2025 results: $75.1M revenue, net loss $146.4M (vs. $162.9M in 2024), and approximately $700M available liquidity. The company advanced programs ABCL635 and ABCL575 into clinical trials, moved two candidates into IND/CTA enabling, and opened a clinical manufacturing facility.
Cumulative partner-initiated program starts rose to 104 and molecules in clinic increased to 19.
AbCellera (Nasdaq: ABCL) will present at three investor conferences in March and April 2026: TD Cowen 46th Annual Health Care Conference on March 4, KeyBanc Capital Markets Healthcare Forum on March 17, and Bloom Burton & Co. Healthcare Investor Conference on April 21–22. A live audio webcast and replay will be posted on the company Investor Relations website closer to each date.
AbCellera (Nasdaq: ABCL) will report full year 2025 financial results on Tuesday, February 24, 2026. The company will host an earnings conference call at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time the same day. A live audio webcast will be accessible via a link on AbCellera's Investor Relations website, and a replay will be available at the same link after the call.
AbCellera (Nasdaq: ABCL) announced dosing of the first patients in the Phase 2 portion of its Phase 1/2 trial of ABCL635, a potential first-in-class non-hormonal therapy for moderate-to-severe vasomotor symptoms (VMS) of menopause. The Phase 2 is a multicenter, randomized, double‑blind, placebo‑controlled Proof-of-Concept study in 80 postmenopausal women. The move to Phase 2 follows an interim review of safety, tolerability, and pharmacodynamic data from Phase 1 healthy volunteers and evidence of high target engagement. With Phase 2 enrollment underway, the company anticipates top-line results for both phases in Q3 2026.
AbCellera (Nasdaq: ABCL) announced a global settlement and patent license agreement with Bruker on December 18, 2025. As part of the deal, Bruker will pay $36 million up front and will make future royalty payments on sales of Bruker's Beacon® Optofluidic platform worldwide through the life of the licensed patents. The agreement resolves the companies' global patent litigation and grants Bruker a license to the covered patents.
AbCellera (Nasdaq: ABCL) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. A live audio webcast will be available via a link posted on AbCellera's Investor Relations website, with a replay accessible after the presentation.
AbCellera (Nasdaq: ABCL) appointed Stephen Quake, D.Phil., to its Board of Directors as an independent director effective November 10, 2025.
Dr. Quake is a prominent scientist and entrepreneur with >300 publications, an h-index of 181, 80+ patents, leadership roles at Stanford and Caltech, and service as founding co-president and later head of science for the Chan Zuckerberg Biohub Network (launch budget ~$600 million). Concurrently, Andrew W. Lo, Ph.D., resigned after joining the board in December 2021 and serving on Audit and Nominating and Corporate Governance Committees.
AbCellera (Nasdaq: ABCL) reported Q3 2025 results for the period ended September 30, 2025. Key operational highlights include starting activities at a new clinical manufacturing facility, substantially completing platform investments, and appointing Sarah Noonberg, M.D., Ph.D. as chief medical officer.
Financials: Revenue $9.0M versus $6.5M a year earlier; net loss $57.1M ($(0.19) per share) versus $51.1M in Q3 2024. R&D spend rose to $55.0M, including $15.0M on two internal programs. Liquidity totaled approximately $680M including $523M cash and $159M government funding.
Operational metrics: 103 partner-initiated program starts with downstreams and 18 molecules in the clinic.
AbCellera (Nasdaq: ABCL) will participate in multiple investor conferences in November and December 2025.
Scheduled events: Truist Securities BioPharma Symposium on November 6, 2025; Stifel Healthcare Conference on November 11–13, 2025; Jefferies Global Healthcare Conference on November 18–20, 2025; and Piper Sandler 37th Annual Healthcare Conference on December 2–4, 2025. Visit the company Investor Relations website for additional information and access details.